Light-Chain (AL) Amyloidosis
Open Access
- 1 November 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 1 (6), 1331-1341
- https://doi.org/10.2215/cjn.02740806
Abstract
Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognize because of its broad range of manifestations and what often are vague symptoms. The clinical syndromes at presentation include nephrotic-range proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines approaches to diagnosis, assessment of disease severity, and treatment of AL amyloidosis.Keywords
This publication has 82 references indexed in Scilit:
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- AL amyloidosis associated with B‐cell lymphoproliferative disorders: Frequency and treatment outcomesAmerican Journal of Hematology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- High‐dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II studyBritish Journal of Haematology, 2004
- Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years LaterMayo Clinic Proceedings, 2004
- Fine‐needle aspiration of abdominal fat pad for amyloid detection: A clinically useful test?Diagnostic Cytopathology, 2004
- An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisBone Marrow Transplantation, 2001
- Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotininEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosisThe American Journal of Cardiology, 1984